LIVZON PHARMA (01513) spent 8.7832 million yuan on September 24 to repurchase 250,000 shares of A shares.
Lizhu Pharmaceutical (01513) announced that the company invested 8.7832 million yuan on September 24, 2024...
LIVZON PHARMA (01513) announced that the company spent 8.7832 million yuan to repurchase 250,000 A shares on September 24, 2024. The repurchase price was between 34.95 yuan and 35.76 yuan per share.
Related Articles
Shenzhen Infinova, a subsidiary of Infinova(002528.SZ), plans to publicly list and transfer 100% of the equity of Hangzhou Science and Technology.
Shenyang Xingqi Pharmaceutical (300573.SZ): The first subject enrolled in the clinical trial of SQ-22031 eye drops for the treatment of moderate to severe dry eye syndrome stage II.
Xuanwu Cloud (02392) spent HK$2263.27 on December 9 to repurchase 2000 shares.
Shenzhen Infinova, a subsidiary of Infinova(002528.SZ), plans to publicly list and transfer 100% of the equity of Hangzhou Science and Technology.
Shenyang Xingqi Pharmaceutical (300573.SZ): The first subject enrolled in the clinical trial of SQ-22031 eye drops for the treatment of moderate to severe dry eye syndrome stage II.
Xuanwu Cloud (02392) spent HK$2263.27 on December 9 to repurchase 2000 shares.
RECOMMEND
Baidu’s AI Ace Kunlunxin Prepares For Hong Kong IPO, Domestic Computing Power Faces Crucial Test
08/12/2025
Institutions Say Short-Term Volatility Does Not Alter Upward Trend Of Hong Kong Stocks, Hang Seng Index Still Expected To Challenge 30,000 Points Next Year
08/12/2025
As The 2025 Central Economic Work Conference Approaches, What New Expectations Lie Ahead For Next Year’s Economic Agenda? Institutions Forecast Five Key Highlights
08/12/2025
